Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QEOMT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
[111In]In-ADCS
|
|||||
| Synonyms |
[111In]In-ADCS
Click to Show/Hide
|
|||||
| Organization |
Kyoto University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
DBCO-Azide Click Chemistry Conjugation
|
|||||
ADC-specific functional property(2027 Update)
Circulating Stability
| Incubation Time | 96h | Release | 2.5% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | Murine plasma | ||||
| Description |
To determine the stability of the CTSB-recognizing chelating agent, RCP of [111In]In-ADCS was analyzed using RP-HPLC after incubation in murine plasma at 37°C for 0, 24, and 96 h.
|
||||
References